Compare Hims and Hers Health Inc (HIMS) vs Tyson Foods, Inc. (TSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs Tyson Foods, Inc. — how do they compare? Hims and Hers Health Inc trades at $29.23 (market cap $6.55B), while Tyson Foods, Inc. trades at $52.44 (market cap $18.41B). The key difference: Tyson Foods, Inc. is far larger — about 2.8× Hims and Hers Health Inc's market cap, and Tyson Foods, Inc. pays a 3.9% dividend while Hims and Hers Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and Tyson Foods, Inc. for 76 Days on average.
| HIMS | TSN | |
|---|---|---|
Market Cap | $6.55B | $18.41B |
Volume | 14,842,814 | 3,757,599 |
Sector | Health | Consumer Staples |
52-Week High | $62.76 | $68.75 |
52-Week Low | $14.52 | $50.47 |
Typical Hold Time | 21 Days | 76 Days |
Enterprise Value | $7.25B | $25.68B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health (HIMS) trades at $29.38, down 0.54% on the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $2.35 billion in 2025 with a net income of $128.37 million, but 2026 projections show a net loss of $142 million. Valuation ratios are elevated with a P/E of 57.14 and EV/EBITDA of 205.86. Recent news highlights multiple securities class action lawsuits filed against the company, creating investor uncertainty.
The outlook is cautious due to profitability concerns and legal risks. Analyst consensus is a Hold with a $32.17 price target, suggesting limited upside. Key risks include ongoing litigation, negative profit margins, and high valuation multiples. Investment appeal hinges on the company's ability to return to profitability and navigate regulatory challenges.
Tyson Foods (TSN) trades at $51.70, down 0.52% with mixed technical signals showing neutral overall but bearish moving averages. The company reported Q2 2026 EPS of $0.99, beating expectations, while Q4 2025 missed. Revenue grew to $54.44B in 2025 with thin 1.03% net margins. Analyst consensus is bullish with 53% buy ratings and $65.40 price target, though recent news highlights challenges in the beef segment and ongoing securities investigations.
The stock presents a value opportunity with low P/S (0.33) and reasonable EV/EBITDA (9.83), but faces significant execution risks from beef segment losses and margin pressure. Upside depends on successful business turnaround and resolution of legal concerns, while current price near 52-week lows offers potential for recovery if fundamentals improve.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About Tyson Foods, Inc.
Tyson Foods is the largest U.S. producer of processed chicken and beef. It's also a large producer of processed pork and protein-based products under the brands Jimmy Dean, Hillshire Farm, Ball Park, Sara Lee, Aidells, State Fair, and Raised & Rooted, to name a few. Tyson sells 81% of its products through various U.S. channels, including retailers (47% in fiscal 2021), food service (32%), and other packaged food and industrial companies (10%). In addition, 11% of the company's revenue comes from exports to Canada, Mexico, Brazil, Europe, China, and Japan.
Read more on TSN →
